On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at three upcoming ...

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the stock, ...

Insulet produces and sells Omnipod, an automated insulin delivery device ... making it the first such system to be cleared for use in both type 1 and type 2 diabetes. In September, the company ...

From wearable glucose monitors to AI-driven health insights, recent advances are giving patients new ways to manage blood ...

PLYMOUTH MEETING, Pa. – AdaptHealth CEO Suzanne Foster is doubling down on efforts to turn around the company’s struggling diabetes business, saying it was “worse” than she initially thought it was.

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its target price boosted by Barclays from $58.00 to $60.00 in a research ...

Insulet stock soared out of a buy zone Friday after the insulin pump-maker "continued the beat-and-raise cadence it has seen in 2024." ...

Revenue grew 26% to $543.9 million, ahead of the $519.5 that analysts forecast. Chief Executive Jim Hollingshead said the company's Omnipod 5 automated insulin delivery system -- which was cleared by ...